The U.S. Food and Drug Administration (FDA) revised the label for Fabhalta (iptacopan) on 2026-06-08, adding a Boxed Warning regarding the risk of serious infections. This significant update highlights the potential for severe infections, especially those caused by encapsulated bacteria.
Background
Fabhalta (iptacopan) is a complement inhibitor. Complement inhibitors are a class of drugs that modulate the complement system, a part of the immune system. The addition of a Boxed Warning indicates a heightened safety concern identified for this drug, necessitating prominent disclosure on its labeling.
What this means
The addition of a Boxed Warning to the Fabhalta label underscores a critical safety consideration for healthcare providers and patients. This warning emphasizes that Fabhalta, as a complement inhibitor, increases the risk of serious infections, particularly those caused by encapsulated bacteria such as Streptococcus pneumoniae and Neisseria meningitidis. Healthcare professionals prescribing Fabhalta must be vigilant in assessing a patient's infection risk profile before initiating treatment. It is crucial to counsel patients thoroughly on the signs and symptoms of serious infections and to advise them to seek immediate medical attention if these occur. Furthermore, clinicians should consider appropriate preventative measures, which may include vaccination against these specific pathogens, in accordance with current clinical guidelines and individual patient risk factors. Ongoing monitoring for any indications of infection is also essential throughout the course of treatment with Fabhalta.
Source
The information regarding this label revision was sourced from the U.S. Food and Drug Administration (FDA). The update, effective 2026-06-08, is documented on the DailyMed platform hosted by the National Library of Medicine (dailymed.nlm.nih.gov), which provides official drug labeling information.